Abstract Background Inflammatory bowel disease (IBD) is a global health problem in which gut microbiota dysbiosis plays a pivotal pathogenic role. Mesenchymal stem cells (MSCs) therapy has emerged as a prospective novel tool for managing IBD. and which can also regulate the composition of gut microbiota. However. https://www.roneverhart.com/Arjo-Sara-Stedy-Stand-Assist-Manual-Patient-Standing-Aid/